Earlier Liver Disease Detection Means Better Outcomes – and You Can Make the Difference

Why It Matters

By catching liver disease before irreversible damage, hepatoSIGHT can expand therapeutic options, reduce costly emergency admissions, and reverse a unique upward mortality trend in the UK.

Key Takeaways

• Over one‑third of emergency‑diagnosed patients die within a year
• 80% of MASH patients remain undiagnosed
• hepatoSIGHT scans existing labs to flag high‑risk patients
• Tool deployed across 6 million South West residents
• Early case‑finding cuts A&E admissions and improves survival

Pulse Analysis

Chronic liver disease is one of the few major causes of death in the United Kingdom where mortality is still rising, despite advances in antiviral and antifibrotic therapies. The condition is silent; patients often avoid help because symptoms are vague and stigma surrounds liver disorders. Primary‑care teams, already stretched by chronic disease management and vaccination programmes, frequently deprioritise routine liver screening. As a result, many cases surface only during acute decompensation, leading to emergency department overload, limited treatment windows, and a one‑third mortality rate for emergently diagnosed patients.

Technology‑enabled case‑finding repurposes existing laboratory data. hepatoSIGHT, created by Predictive Health Intelligence, applies algorithmic filters to routine blood tests—liver enzymes, platelets, iron studies—to generate a shortlist of high‑risk patients. Rolled out across a six‑million‑person cohort in England’s South West, it has already uncovered thousands of hidden cases, from common MASH to rarer haemochromatosis and primary biliary cholangitis. Early pilots show faster referrals and higher diagnostic yield without extra lab costs.

Systematic case‑finding eases pressure on A&E by shifting patients into preventive pathways, freeing beds for true emergencies. Early intervention expands treatment options—lifestyle programmes, fibrosis‑halting drugs, curative antivirals—improving survival and quality of life. For a budget‑constrained NHS, scalable tools like hepatoSIGHT illustrate how data‑driven precision medicine can deliver cost‑effective gains. Nationwide adoption could standardise liver‑risk screening, turning a rising mortality trend into a declining one.